Georgia 2025-2026 Regular Session

Georgia House Bill HB1361

Caption

Pharmacies; compounding of certain active pharmaceutical ingredients; provisions

Impact

If enacted, HB 1361 would significantly strengthen the regulatory framework surrounding pharmaceuticals in Georgia, particularly for compounded drugs. The bill mandates that only pharmaceutical grade active ingredients can be used in compounding, which aligns Georgia's regulations with federal standards. It also introduces mechanisms for increased compliance, such as documentation requirements and penalties for violations, including fines and potential revocation of licenses. Consequently, this may improve drug safety for patients by ensuring that compounded medications are prepared under stringent conditions, thus reducing the risk of contamination or misuse.

Summary

House Bill 1361 focuses on regulating the compounding of certain active pharmaceutical ingredients within Georgia. The bill outlines the necessary requirements for manufacturers and wholesalers involved in the sale, transfer, or distribution of compounded drugs. It emphasizes the importance of ensuring that active pharmaceutical ingredients comply with established standards and provides definitions for critical terms such as 'active pharmaceutical ingredient,' 'human drug establishment,' and 'pharmaceutical grade product.' These definitions help clarify the conditions under which compounding can occur and the requisite quality controls that must be met.

Contention

However, the bill may face contention as stakeholders in the pharmacy sector discuss its implications. Concerns might arise regarding the feasibility of compliance for smaller pharmacies, particularly those that may not have the resources to meet the rigorous documentation and testing requirements mandated by HB 1361. Moreover, some may argue that while stricter regulations are essential for safety, they could unintentionally limit access to certain compounded medications that patients rely upon. Balancing patient safety, access to medications, and manageable compliance burdens will be crucial as discussions around this bill continue.

Companion Bills

No companion bills found.

Previously Filed As

GA H0877

Active Pharmaceutical Ingredients

GA H1407

Compounding Pharmacies

GA SB00434

An Act Concerning Compounding Pharmacies.

GA HB07179

An Act Concerning Pharmaceutical Marketing And Pharmaceuticals.

GA HB1407

Compounding Pharmacies:

GA HB2208

Pharmacists; pharmacies; reimbursement costs; appeals

GA HB2196

Pharmacists; pharmacies; reimbursement costs; appeals

GA HB127

Pharmaceuticals; prohibiting the Board of Pharmacy from disciplining pharmacists who recommend off-label use of a drug; allowing over-the-counter sale of Ivermectin and Hydroxychloroquine.

GA SB1309

Pharmacists; care standard; prescriptions

GA SB140

Optometrists; doctors of optometry to dispense and sell pharmaceutical agents to patients under certain conditions; provide

Similar Bills

AR HB1301

To Amend The Prior Authorization Transparency Act.

CT SB01355

An Act Concerning Prescription Drugs, Devices And Nonlegend Drugs.

AR HB1531

To Prohibit Pharmaceutical Manufacturers From Restricting Or Limiting Prescription Medications To A Limited Distribution Network Of Out-of-state Pharmacies.

FL S0860

Compounded Drugs

DE SJR7

Directing The State Employee Benefits Committee And The Secretary Of Human Resources To Engage With Independent Consultants And Other Supply Chain Tactics For Cost Containment Of Prescription Drugs For State Employees And Retirees Insurance Programs.

HI HB2224

Relating To Medicaid.

CA AB1979

Health care services: artificial intelligence.

CT HB07179

An Act Concerning Pharmaceutical Marketing And Pharmaceuticals.